Purpose: evaluate the clinical outcomes of Rhabdomyolysis in COVID-19 patients. Method: The present study is a systematic review and meta-analysis (PRISMA guidelines) study based on information collected from regular search of Internet resources using logical functions between keywords in PubMed, Scopus, Science Direct, Embase and scholar. Google search engine, uses English keywords between January 2019 and March 2022. 95% confidence interval on effect size were done with fixed effect model and invariance method. Meta-analysis was performed using STATA.V16 software. Results:general search for relevant sources was Rhabdomyolysis and COVID-19, 317 articles, then reduced this number to 187 articles by applying the years filter; Finally, six articles that were published between January 2019 and March 2022 and met the inclusion criteria, entered the analysis. Effect size of Myalgias and Renal replacement therapy in COVID-19 patients was 99% (ES 99%, 95% confidence interval 88 to 100%) and 0.42% (ES 42%, 95% confidence interval 20 to 64%), respectively. Conclusion:Rhabdomyolysis is one of the most important aspects of COVID-19, which has been reported in few studies. Monitoring creatine kinase levels can be a good guide for physicians to make important treatment decisions. Early diagnosis of Rhabdomyolysis can prevent renal replacement therapy in COVID-19 patients.

Rhabdomyolysis, COVID-19, Renal Replacement Therapy